Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

02.15.24

LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

01.10.24

Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months Results demonstrated a 61% increase in preventative drug prescriptions among patients in the high-risk

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

11.14.23

LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today

Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14

11.07.23

LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

10.06.23

LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and

Renalytix Reports Full Year Fiscal 2023 Results

09.28.23

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care,

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

09.25.23

LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live

Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

09.07.23

Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled

Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

08.03.23

World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease LONDON and SALT LAKE CITY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc  (LSE: RENX) (NASDAQ:RNLX) announces the launch of its